Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc. (symbol: RBOT) is at the forefront of innovation in the field of surgical robotics. The company is dedicated to enhancing the capabilities of surgeons and improving patient outcomes through advanced technological solutions. Vicarious Surgical has developed a unique surgical robot that combines human-like dexterity with the world's first virtual-reality surgical camera, enabling surgeons to perform minimally invasive procedures with the same ease as traditional open surgery.
The company’s flagship product, the Vicarious Surgical Robotic System, is specifically designed for abdominal surgeries. It offers 3D visualization and precise control, all through a single port, which significantly reduces the invasiveness of surgical procedures. This groundbreaking technology aims to expand global access to high-quality surgical care.
Vicarious Surgical's approach redefines what is possible in surgical robotics by integrating cutting-edge virtual reality and robotics technology. The company has achieved significant milestones in recent years, including key partnerships and notable advancements in their robotic systems.
Financially, Vicarious Surgical continues to show promise with robust investments and strategic collaborations that drive its growth and innovation. The company remains committed to pushing the boundaries of medical technology, with ongoing projects focused on further enhancing their systems and expanding their applications.
For investors and stakeholders, Vicarious Surgical represents a compelling opportunity in the rapidly evolving field of medical technology. The company’s mission to improve surgical outcomes and patient care through revolutionary robotics sets it apart as a leader in the industry.
Stay updated with the latest news and developments from Vicarious Surgical to understand its impact and progress in the surgical robotics landscape.
Vicarious Surgical, Inc. (NYSE:RBOT) has successfully qualified its cleanroom for manufacturing the Vicarious System, enhancing its capabilities for precision assembly. This qualification ensures adherence to stringent efficiency and quality standards, marking a significant step towards market readiness. The Vicarious System aims to improve surgical outcomes by facilitating procedures through a single port, promoting faster patient recovery. CEO Adam Sachs emphasized the importance of a quality-controlled manufacturing process in achieving better healthcare outcomes.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced the appointment of John Mazzola as vice president of operations. With over 30 years in the medical device industry, Mazzola aims to enhance the company’s manufacturing strategies for its next-generation surgical robotics. Prior to joining Vicarious, he held senior roles at Becton Dickinson, overseeing 10 manufacturing sites. CEO Adam Sachs expressed confidence in Mazzola's expertise to drive operational growth. Mazzola's active involvement in industry associations adds to his credentials.
Vicarious Surgical (NYSE: RBOT, RBOT WS) reported preliminary unaudited financial results for Q4 and the full year 2021. The company experienced a significant increase in operating expenses, totaling $18.2 million in Q4, up 380% year-over-year. Adjusted net loss for Q4 was $18.2 million, or $0.15 per share, compared to a loss of $3.8 million, or $0.04 per share in the prior year. Full year operating expenses reached $38.6 million, reflecting a 197% increase. Cash and cash equivalents stood at $173.5 million as of December 31, 2021.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in two upcoming virtual investor conferences. The Cowen 42nd Annual Healthcare Conference will feature a presentation on
Vicarious Surgical Inc. (NYSE: RBOT) will release its fourth quarter 2021 financial results on March 3, 2022, after market close. A conference call, starting at 4:30 p.m. ET, will follow to discuss the results. Investors can participate by calling 1 (646) 904 5544 domestically or +1 (929) 526 1599 internationally. Vicarious Surgical, founded in 2014, focuses on enhancing surgical efficiency and reducing healthcare costs using proprietary robotic technology.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will engage in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16 at 4:00 p.m. Eastern Time. The company focuses on enhancing surgical procedures through next-generation robotic technology, which has been recognized by the FDA with a Breakthrough Device Designation. Founded in 2014, Vicarious Surgical aims to improve patient outcomes while reducing healthcare costs. The event is accessible via BTIG representatives.
Vicarious Surgical has been recognized with three awards in Built In’s 2022 Best Places To Work Awards, including Best Places to Work, Best Midsize Companies to Work for, and Best Paying Companies in Boston. The awards program evaluates company data on compensation and benefits, adapting to the changing needs of tech professionals. CEO Adam Sachs emphasized the company's commitment to employee success as it grows. Founded in 2014, Vicarious Surgical focuses on innovative surgical robotics and has received Breakthrough Device Designation from the FDA for its technology.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation will be accessible from November 22, 2021, at 10:00 a.m. Eastern Time on their website. Founded in 2014, Vicarious Surgical is innovating surgical procedures using advanced robotics and virtual reality technology, aiming to enhance efficiency and patient outcomes. Their technology is recognized with Breakthrough Device Designation by the FDA, marking a significant milestone in surgical robotics.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its third quarter 2021 financial results, marking its entry into public markets. The company posted an operating expense of $8.6 million, a 156.2% increase from the previous year. R&D expenses rose to $5.2 million while general and administrative costs increased to $2.5 million. The net loss reached $65.5 million, showing a significant increase from $3.3 million in Q3 2020, resulting in a net loss per share of $0.71. However, cash reserves stood strong at $185 million as of September 30, 2021.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
What does Vicarious Surgical Inc. specialize in?
What is the Vicarious Surgical Robotic System?
How does Vicarious Surgical's technology benefit surgeons?
What makes Vicarious Surgical's approach unique?
Where can I find the latest news about Vicarious Surgical Inc.?
What are the recent achievements of Vicarious Surgical Inc.?
How does the Vicarious Surgical Robotic System improve patient outcomes?
Is Vicarious Surgical Inc. involved in any partnerships?
What is the focus area of Vicarious Surgical's robotic system?
How does Vicarious Surgical's technology expand global access to surgical care?
